Cargando…

Analysis of the Clinical Significance and Safety of Interferon in the Treatment of Chronic Myeloproliferative Tumors

OBJECTIVE: To investigate the clinical significance and safety of interferon in the treatment of chronic myeloproliferative tumors (MPN). METHODS: In this prospective study, a total of 120 patients with advanced chronic MPN admitted to our hospital between April 2016 and August 2020 were assessed fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Fenglei, Yin, Juan, Xu, Weixing, Li, Shuchen, Zhang, Wei, Wang, Juan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126710/ https://www.ncbi.nlm.nih.gov/pubmed/35615245 http://dx.doi.org/10.1155/2022/6551868

Ejemplares similares

The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms
por: Yoon, Seug Yun, et al.
Publicado: (2021)

Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
por: How, Joan, et al.
Publicado: (2020)

New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms
por: Hasselbalch, Hans C., et al.
Publicado: (2021)

Long-acting interferon: pioneering disease modification of myeloproliferative neoplasms
por: Yoon, Seug Yun, et al.
Publicado: (2023)

Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment
por: Kjær, Lasse, et al.
Publicado: (2016)

Recent advances in diagnosis and treatment of chronic myeloproliferative neoplasms
por: Guglielmelli, Paola, et al.
Publicado: (2010)

Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
por: Hasselbalch, Hans Carl, et al.
Publicado: (2018)

Interferon Alpha Therapy Increases Pro-Thrombotic Biomarkers in Patients with Myeloproliferative Neoplasms
por: Faille, Dorothée, et al.
Publicado: (2020)

Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms
por: Saleiro, Diana, et al.
Publicado: (2022)

Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib
por: Zhao, Fang, et al.
Publicado: (2018)

Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms
por: Andıç, Neslihan, et al.
Publicado: (2016)

Philadelphia-negative chronic myeloproliferative neoplasms
por: Bittencourt, Rosane Isabel, et al.
Publicado: (2012)

Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
por: Begna, K, et al.
Publicado: (2016)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms
por: Soyer, Nur, et al.
Publicado: (2017)

Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg
por: Yang, Xiaoan, et al.
Publicado: (2022)

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms
por: Malcovati, Luca, et al.
Publicado: (2011)

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
por: Ianotto, Jean-Christophe, et al.
Publicado: (2018)

Chronic Myeloproliferative Neoplasms: a Collaborative Approach
por: Pieri, Lisa, et al.
Publicado: (2010)

Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm
por: Zielinska, Patrycja, et al.
Publicado: (2014)

Chronic Myeloproliferative Neoplasms: Some Remaining Challenges
por: Mughal, Tariq I., et al.
Publicado: (2018)

Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms
por: Marin Oyarzún, Cecilia P., et al.
Publicado: (2019)

Pulmonary hypertension in patients with chronic myeloproliferative disorders
por: Adir, Yochai, et al.
Publicado: (2015)

Editorial: Novel Treatment Strategies for Myeloproliferative Neoplasms
por: Lim, Ken-Hong, et al.
Publicado: (2021)

Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α
por: Aruna,, et al.
Publicado: (2018)

The Clinical Significance of Autoantibodies in Hepatitis C Patients Submitted to Interferon Treatment
por: Rodrigues-Pinto, Eduardo, et al.
Publicado: (2015)

Children and Adolescents with Chronic Myeloproliferative Neoplasms: Still an Unmet Biological and Clinical Need?
por: Mughal, Tariq I., et al.
Publicado: (2019)

P1051: CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS
por: Krecak, Ivan, et al.
Publicado: (2023)

(32)P in the treatment of myeloproliferative disorders
por: Lawless, Sarah, et al.
Publicado: (2016)

Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis
por: Fang, Zijian, et al.
Publicado: (2023)

Myelodysplastic/Myeloproliferative Neoplasms, Unclassifiable (MDS/MPN, U): Natural history and clinical outcome by treatment strategy
por: DiNardo, CD, et al.
Publicado: (2014)

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms
por: Ferrer-Marín, Francisca, et al.
Publicado: (2021)

Retrospective analysis of the clinical features of 172 patients with BCR-ABL1-negative chronic myeloproliferative neoplasms
por: Lin, Xiaolan, et al.
Publicado: (2020)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

A detailed characterization of peripheral blood lymphocytes in patients with myeloproliferative disease treated with pegylated-interferon alpha
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2015)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

A review of current knowledge of myeloproliferative disorders in the horse
por: Satué, Katy, et al.
Publicado: (2021)

The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia
por: Yap, Yee Yee, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7j8o9lbsbhj9le28kcomh4kb6c